Extended anticoagulation after venous thromboembolism: should it be done?
Caio Julio Cesar Dos Santos FernandesDaniela CalderaroBruna PilotoSusana HoetteCarlos Vianna Poyares JardimRogério SouzaPublished in: Therapeutic advances in respiratory disease (2020)
Most physicians understand venous thromboembolism (VTE) to be an acute and time-limited disease. However, pathophysiological and epidemiological data suggest that in most patients VTE recurrence risk is not resolved after the first 6 months of anticoagulation. Recurrence rates are high and potentially life-threatening. In these cases, it would make sense to prolong anticoagulation for an undetermined length of time. However, what about the bleeding rates, induced by prolonged anticoagulation? Would they not outweigh the benefit of reducing the VTE recurrent risk? How long should anticoagulation be continued, and should all patients suffering from VTE be provided with extended anticoagulation? This review will address the most recent data concerning extended anticoagulation in VTE secondary prophylaxis. The reviews of this paper are available via the supplementary material section.
Keyphrases
- venous thromboembolism
- direct oral anticoagulants
- end stage renal disease
- newly diagnosed
- ejection fraction
- atrial fibrillation
- chronic kidney disease
- prognostic factors
- primary care
- peritoneal dialysis
- systematic review
- randomized controlled trial
- big data
- electronic health record
- patient reported outcomes
- artificial intelligence
- intensive care unit
- data analysis
- drug induced